Nuclear PD-L1 promotes EGR1-mediated angiogenesis and accelerates tumorigenesis

Targeting programmed cell death protein ligand 1 (PD-L1) remains one of the most essential immunotherapies in cancer(1,2). PD-L1 has been detected in the nucleus in multiple malignancies, playing an oncogenic role independent of immune checkpoint regulation(3–5). Howbeit, the regulatory function of...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Jie, Zhuang, Ai, Gu, Xiang, Hua, Yu, Yang, Ludi, Ge, Shengfang, Ruan, Jing, Chai, Peiwei, Jia, Renbing, Fan, Xianqun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10050073/
https://www.ncbi.nlm.nih.gov/pubmed/36977660
http://dx.doi.org/10.1038/s41421-023-00521-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10050073/
https://www.ncbi.nlm.nih.gov/pubmed/36977660
http://dx.doi.org/10.1038/s41421-023-00521-7

Ejemplares similares